A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

NCT01740609 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-06-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.

Conditions

  • Healthy

Interventions

DRUG

Placebo

Placebo

BIOLOGICAL

PF-06342674 Dose A

Single SC Dose

BIOLOGICAL

PF-06342674 Dose B

Single SC Dose

BIOLOGICAL

PF-06342674 Dose C

Single SC Dose

BIOLOGICAL

PF-06342674 Dose D

Single SC Dose

BIOLOGICAL

PF-06342674 Dose E

Single SC Dose

BIOLOGICAL

PF-06342674 Dose F

Single IV Dose

BIOLOGICAL

PF-06342674 Dose G

Single SC Dose

BIOLOGICAL

PF-06342674 Dose H

Single IV Dose

BIOLOGICAL

PF-06342674 Dose I

Single SC Dose

BIOLOGICAL

PF-06342674 Dose J

Single IV Dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01740609 on ClinicalTrials.gov